Assessing early tubular protective effects of SGLT2 inhibitor empagliflozin against type 2 diabetes mellitus using functional magnetic resonance imaging-Reference-Cited by-同舟云学术

Assessing early tubular protective effects of SGLT2 inhibitor empagliflozin against type 2 diabetes mellitus using functional magnetic resonance imaging

Published:2023-12-20 Issue: Volume: Page:
ISSN:1432-5233
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Zhang Chuangbiao,Zhu Beibei,Feng Youzhen,Cheng Zhongyuan,Cai Xiangran,Feng Lie,Li Jiaying^ORCID,Lu Xiaohua

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00592-023-02220-x.pdf

Reference30 articles.

1. Levin A et al (2013) Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1–150

2. McQueen RB et al (2017) Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ 20(6):585–591

3. Sun H et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119

4. Hoogeveen EK (2022) The epidemiology of diabetic kidney disease. Kidney Dial 2(3):433–442

5. Duan J et al (2019) Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in Chinese rural residents: a cross-sectional survey. Sci Rep 9(1):10408

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes;Frontiers in Endocrinology;2024-08-30